List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/167504/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Therapeutic drug monitoring-enabled long-term use of linezolid for the successful treatment of refractory pyogenic spondylodiscitis without development of thrombocytopenia: A case report. Journal of Orthopaedic Science, 2023, 28, 1587-1591.	1.1	2
2	Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. European Journal of Clinical Pharmacology, 2022, 78, 279-286.	1.9	3
3	Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report. Case Reports in Oncology, 2022, 14, 1277-1282.	0.7	3
4	Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients. Journal of Oncology Pharmacy Practice, 2022, 28, 31-38.	0.9	1
5	A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain. Anticancer Research, 2022, 42, 343-348.	1.1	0
6	Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer. Supportive Care in Cancer, 2022, 30, 4081.	2.2	2
7	Using Japanese big data to investigate novel factors and their highâ€risk combinations that affect vancomycinâ€induced nephrotoxicity. British Journal of Clinical Pharmacology, 2022, 88, 3241-3255.	2.4	7
8	Evaluation of the strategies to reduce thirdâ€generation oral cephalosporins in dentistry at a Japanese academic hospital: An interrupted time series analysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1010-1019.	1.5	1
9	Hepatic drug metabolism in older people with body composition changes. Geriatrics and Gerontology International, 2022, 22, 449-454.	1.5	2
10	Development of a Method of Liquid Chromatography Coupled with Tandem Mass Spectrometry for Simultaneous Determination of Linezolid and Tedizolid in Human Plasma. Biological and Pharmaceutical Bulletin, 2022, 45, 421-428.	1.4	3
11	A Survey Using a Terminal Care Attitude Scale Intended for Oncologists and Palliative Care Staff. Palliative Care Research, 2022, 17, 51-58.	0.0	0
12	Correlation between antibiotic use and antibiotic resistance: A multicenter study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system in Hokkaido, Japan. American Journal of Infection Control, 2022, , .	2.3	2
13	Efficacy Survey of Naldemedine in the Poor-performance Status Group. Yakugaku Zasshi, 2022, 142, 755-760.	0.2	1
14	Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. European Journal of Clinical Pharmacology, 2021, 77, 381-388.	1.9	5
15	Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Supportive Care in Cancer, 2021, 29, 3277-3285.	2.2	8
16	Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli. Journal of Infection and Chemotherapy, 2021, 27, 473-479.	1.7	3
17	Hypertriglyceridemia induced by S-1: A novel case report and review of the literature. Journal of Oncology Pharmacy Practice, 2021, 27, 1020-1025.	0.9	7
18	A new system to evaluate characteristics of Niemann-Pick C1 Like 1-mediated cholesterol transport using Xenopus laevis oocytes. Biochimica Et Biophysica Acta - Biomembranes, 2021, 1863, 183508.	2.6	2

#	Article	IF	CITATIONS
19	Evaluation of Chemotherapy Regimen Management Practice by Oncology-Specialized and Non-specialized Pharmacists Collaboration. Biological and Pharmaceutical Bulletin, 2021, 44, 293-297.	1.4	2
20	Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report. Case Reports in Oncology, 2021, 14, 207-211.	0.7	2
21	Probiotic Prescription Status of Pediatric Patients with Otitis Media Receiving Oral Amoxicillin or Amoxicillin/Clavulanate from April 2016 to March 2017 Using a Japanese Health Insurance Claims Database. Biological and Pharmaceutical Bulletin, 2021, 44, 448-452.	1.4	Ο
22	Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study. Biological and Pharmaceutical Bulletin, 2021, 44, 474-477.	1.4	3
23	Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors. Biological and Pharmaceutical Bulletin, 2021, 44, 593-598.	1.4	4
24	Sarcopenia in a patient with most serious complications after highly invasive surgeries treated with nutrition, rehabilitation, and pharmacotherapy: a case report. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 16.	1.0	2
25	Benzodiazepine Concentrations in the Breast Milk and Plasma of Nursing Mothers: Estimation of Relative Infant Dose. Breastfeeding Medicine, 2021, 16, 424-431.	1.7	19
26	Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis. Supportive Care in Cancer, 2021, 29, 7747-7753.	2.2	14
27	Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 21.	1.0	3
28	An imaging approach for determining the mechanism of enhancement of intestinal absorption of an L-theanine supplement. PLoS ONE, 2021, 16, e0253066.	2.5	0
29	Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report. Case Reports in Oncology, 2021, 14, 806-811.	0.7	3
30	Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Supportive Care in Cancer, 2021, 29, 8059-8067.	2.2	6
31	A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database. Expert Opinion on Drug Safety, 2021, 20, 1257-1266.	2.4	0
32	Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant Staphylococcus aureus antibiotics by an antimicrobial stewardship team. American Journal of Infection Control, 2021, 49, 1493-1498.	2.3	4
33	Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database. Biological and Pharmaceutical Bulletin, 2021, 44, 1151-1155.	1.4	1
34	cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability. Biological and Pharmaceutical Bulletin, 2021, 44, 1101-1110.	1.4	1
35	Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods. British Journal of Clinical Pharmacology, 2021, , .	2.4	8
36	Severe hypertriglyceridemia induced by S-1: Subsequent case series of four patients and further review of the literature. International Journal of Clinical Pharmacology and Therapeutics, 2021, 59, 787-793.	0.6	1

#	Article	IF	CITATIONS
37	Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database. Biological and Pharmaceutical Bulletin, 2021, 44, 1499-1505.	1.4	4
38	Pregabalin Attenuates Carboplatin-Induced Akathisia-Like Neuropathy: A Novel Case Report. Case Reports in Oncology, 2021, 14, 1418-1421.	0.7	1
39	Effects of piperacillin/tazobactam or cefepime on folinate dose in patients receiving high-dose methotrexate: A retrospective cohort study using Japanese administrative claims data. Journal of Oncology Pharmacy Practice, 2021, , 107815522110347.	0.9	0
40	Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients. Journal of Infection and Chemotherapy, 2021, , .	1.7	4
41	Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation. Biological and Pharmaceutical Bulletin, 2021, 44, 1819-1823.	1.4	3
42	Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment. Scientific Reports, 2021, 11, 23298.	3.3	3
43	Influence of gastrointestinal activity on the absorption of nilotinib. Drug Metabolism and Pharmacokinetics, 2020, 35, 102-110.	2.2	4
44	Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Supportive Care in Cancer, 2020, 28, 3251-3257.	2.2	5
45	Enhancement of intestinal absorption of coenzyme Q10 using emulsions containing oleyl polyethylene acetic acids. European Journal of Pharmaceutical Sciences, 2020, 142, 105144.	4.0	9
46	Transfer of orally administered hyaluronan to the lymph. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 210-213.	4.3	8
47	Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice. PLoS ONE, 2020, 15, e0236789.	2.5	22
48	Comparison of interactions between warfarin and cephalosporins with and without the N-methyl-thio-tetrazole side chain. Journal of Infection and Chemotherapy, 2020, 26, 1224-1228.	1.7	5
49	Association of the ward pharmacy service with active implementation of therapeutic drug monitoring for vancomycin and teicoplanin—an epidemiological surveillance study using Japanese large health insurance claims database. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 18.	1.0	10
50	A cross-sectional exploratory survey on occurrence of triple-whammy prescription pattern in Japan. International Journal of Clinical Pharmacy, 2020, 42, 1369-1373.	2.1	3
51	A Risk Prediction Flowchart of Vancomycin-Induced Acute Kidney Injury to Use When Starting Vancomycin Administration: A Multicenter Retrospective Study. Antibiotics, 2020, 9, 920.	3.7	13
52	Nonsteroidal antiâ€inflammatory drugs use in patients with chronic kidney disease are often prescribed from different clinicians than those who diagnosed them. Pharmacoepidemiology and Drug Safety, 2020, 29, 873-880.	1.9	5
53	A New Algorithm Optimized for Initial Dose Settings of Vancomycin Using Machine Learning. Biological and Pharmaceutical Bulletin, 2020, 43, 188-193.	1.4	22
54	Serotonin Syndrome Developing Immediately after the Initiation of Low-Dose Methadone Therapy: A Case Report. Case Reports in Oncology, 2020, 13, 281-284.	0.7	5

#	Article	IF	CITATIONS
55	Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer. Biological and Pharmaceutical Bulletin, 2020, 43, 762-766.	1.4	4
56	Transport via Niemann-Pick C1 Like 1 contributes to the intestinal absorption of ubiquinone. Drug Metabolism and Pharmacokinetics, 2020, 35, 527-533.	2.2	12
57	Prescription of Colchicine with Other Dangerous Concomitant Medications: A Nation-Wide Survey Using the Japanese Claims Database. Biological and Pharmaceutical Bulletin, 2020, 43, 1519-1525.	1.4	8
58	Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors. Biological and Pharmaceutical Bulletin, 2020, 43, 1969-1974.	1.4	7
59	Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells. Biological and Pharmaceutical Bulletin, 2019, 42, 1805-1813.	1.4	3
60	Higher incidence of acute kidney injury in patients treated with piperacillin/tazobactam than in patients treated with cefepime: a single-center retrospective cohort study. Journal of Pharmaceutical Health Care and Sciences, 2019, 5, 13.	1.0	20
61	Comparison of Predictive Performance of Drug Dose Settings Using Renal Function Estimation Equations Based on the Japanese Population: A Preliminary Retrospective Study Using Vancomycin Dosing Data. BPB Reports, 2019, 2, 80-85.	0.3	Ο
62	Enhancement of lymphatic transport of lutein by oral administration of a solid dispersion and a self-microemulsifying drug delivery system. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 171-176.	4.3	28
63	Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving lowâ€dose dasatinib therapy. Geriatrics and Gerontology International, 2018, 18, 505-507.	1.5	3
64	Improvement of renal function estimation equations for elderly <scp>Japanese</scp> people. Health Science Reports, 2018, 1, e85.	1.5	6
65	Inhibitory effect of ezetimibe can be prevented by an administration interval of 4Âh between αâ€ŧocopherol and ezetimibe. Biopharmaceutics and Drug Disposition, 2017, 38, 280-289.	1.9	3
66	Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) ― Digest Version ―. Circulation Journal, 2017, 81, 581-612.	1.6	33
67	Difference in the Dissolution Behaviors of Tablets Containing Polyvinylpolypyrrolidone (PVPP) Depending on Pharmaceutical Formulation After Storage Under High Temperature and Humid Conditions. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 511.	2.1	3
68	Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation. Journal of Pharmaceutical Health Care and Sciences, 2016, 2, 18.	1.0	8
69	An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components <i>via</i> Niemann–Pick C1-Like 1. Biological and Pharmaceutical Bulletin, 2016, 39, 301-307.	1.4	13
70	Schedule-Dependent Cytotoxicity of Etoposide and Cyclophosphamide in P-Glycoprotein-Expressing Human Leukemic K-562 Cells. Biological and Pharmaceutical Bulletin, 2014, 37, 1323-1329.	1.4	5
71	Emulsification Using Highly Hydrophilic Surfactants Improves the Absorption of Orally Administered Coenzyme Q10. Biological and Pharmaceutical Bulletin, 2013, 36, 2012-2017.	1.4	17
72	Intracellular Uptake Mechanism of Lutein in Retinal Pigment Epithelial Cells. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 494.	2.1	16

#	Article	IF	CITATIONS
73	Mutual Inhibition between Carvedilol Enantiomers during Racemate Glucuronidation Mediated by Human Liver and Intestinal Microsomes. Biological and Pharmaceutical Bulletin, 2012, 35, 151-163.	1.4	12
74	Schedule-Dependent Cytotoxicity of Etoposide (VP-16) and Cyclophosphamide in Leukemia Cell Line K-562. Biological and Pharmaceutical Bulletin, 2012, 35, 1132-1136.	1.4	2
75	Involvement of Cholesterol Membrane Transporter Niemann-Pick C1-Like 1 in the Intestinal Absorption of Lutein. Journal of Pharmacy and Pharmaceutical Sciences, 2012, 15, 256.	2.1	40
76	Estimation of the duration after methamphetamine injection using a pharmacokinetic model in suspects who caused fatal traffic accidents. Legal Medicine, 2012, 14, 191-196.	1.3	1
77	Successful transplantation of rat hearts subjected to extended cold preservation with a novel preservation solution. Transplant International, 2012, 25, 696-706.	1.6	15
78	Uptake Mechanism of Trientine by Rat Intestinal Brush-border Membrane Vesicles. Journal of Pharmacy and Pharmacology, 2011, 48, 517-521.	2.4	13
79	The Mechanism of Excretion of Trientine from the Rat Kidney: Trientine is not Recognized by the H+/Organic Cation Transporter. Journal of Pharmacy and Pharmacology, 2011, 49, 426-429.	2.4	6
80	A Structure-Relationship Study of the Uptake of Aliphatic Polyamine Compounds by Rat Intestinal Brush-border Membrane Vesicles. Journal of Pharmacy and Pharmacology, 2011, 49, 511-515.	2.4	2
81	Ionic-diffusion Potential-dependent Transport of a New Quinolone, Sparfloxacin, Across Rat Intestinal Brush-border Membrane. Journal of Pharmacy and Pharmacology, 2011, 50, 627-634.	2.4	2
82	The pH Dependent Uptake of Enoxacin by Rat Intestinal Brush-border Membrane Vesicles. Journal of Pharmacy and Pharmacology, 2011, 44, 722-726.	2.4	22
83	The Stimulative Effect of Diffusion Potential on Enoxacin Uptake across Rat Intestinal Brush-border Membranes. Journal of Pharmacy and Pharmacology, 2011, 46, 676-679.	2.4	11
84	Comparison of Transport Characteristics of Amino $\hat{l}^2$ -Lactam Antibiotics and Dipeptides Across Rat Intestinal Brush Border Membrane. Journal of Pharmacy and Pharmacology, 2011, 41, 628-632.	2.4	45
85	Transport Characteristics of Cephalosporin Antibiotics Across Intestinal Brush-border Membrane in Man, Rat and Rabbit. Journal of Pharmacy and Pharmacology, 2011, 44, 968-972.	2.4	35
86	Effect of Chlorpromazine on the Permeability of β-Lactam Antibiotics Across Rat Intestinal Brush Border Membrane Vesicles. Journal of Pharmacy and Pharmacology, 2011, 40, 701-705.	2.4	20
87	Transport characteristics of ceftibuten, cefixime and cephalexin across human jejunal brush-border membrane. Journal of Pharmacy and Pharmacology, 2011, 43, 882-884.	2.4	30
88	The Inhibitory Effects of Cephalosporin and Dipeptide on Ceftibuten Uptake by Human and Rat Intestinal Brush-border Membrane Vesicles. Journal of Pharmacy and Pharmacology, 2011, 46, 680-684.	2.4	11
89	Contribution of Passive Transport Mechanisms to the Intestinal Absorption of β-Lactam Antibiotics. Journal of Pharmacy and Pharmacology, 2011, 42, 314-318.	2.4	39
90	H+ coupled transport of orally active cephalosporins lacking an α-amino group across brush-border membrane vesicles from rat small intestine. Journal of Pharmacy and Pharmacology, 2011, 43, 433-435.	2.4	20

#	Article	IF	CITATIONS
91	The Transport Mechanism of an Organic Cation, Disopyramide, by Brush-border Membranes. Comparison Between Renal Cortex and Small Intestine of the Rat. Journal of Pharmacy and Pharmacology, 2011, 45, 419-424.	2.4	18
92	Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib. Biological and Pharmaceutical Bulletin, 2011, 34, 433-435.	1.4	52
93	Effect of 5-Fluorouracil Treatment on SN-38 Absorption from Intestine in Rats. Biological and Pharmaceutical Bulletin, 2011, 34, 1418-1425.	1.4	11
94	Protective Effect of Soy Isoflavone Genistein on Ischemia-Reperfusion in the Rat Small Intestine. Biological and Pharmaceutical Bulletin, 2011, 34, 1448-1454.	1.4	23
95	Pharmacokinetic properties of lutein emulsion after oral administration to rats and effect of food intake on plasma concentration of lutein. Biopharmaceutics and Drug Disposition, 2011, 32, 151-158.	1.9	28
96	Protective effect of lutein after ischemia-reperfusion in the small intestine. Food Chemistry, 2011, 127, 893-898.	8.2	21
97	In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. International Journal of Pharmaceutics, 2011, 403, 136-138.	5.2	719
98	The Presence of an Na+/Spermine Antiporter in the Rat Renal Brush-border Membrane. Journal of Pharmacy and Pharmacology, 2010, 51, 279-284.	2.4	12
99	Penetration of linezolid into rabbit intervertebral discs and surrounding tissues. European Spine Journal, 2010, 19, 2149-2155.	2.2	10
100	Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Biophysical Chemistry, 2010, 147, 59-65.	2.8	7
101	Grapefruit juice enhance the uptake of coenzyme Q10 in the human intestinal cell-line Caco-2. Food Chemistry, 2010, 120, 552-555.	8.2	12
102	In Vitro Evaluation of Anticancer Effects of Lung Cancer Chemotherapy Regimens. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2010, 36, 220-226.	0.1	2
103	Regulatory mechanisms of SNAT2, an amino acid transporter, in L6 rat skeletal muscle cells by insulin, osmotic shock and amino acid deprivation. Amino Acids, 2009, 36, 219-230.	2.7	27
104	Functional analysis of phenolsulfonphthalein transport system in Long–Evans Cinnamon rats. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 270-275.	2.6	0
105	Interaction of Coenzyme Q10 with the Intestinal Drug Transporter P-Glycoprotein. Journal of Agricultural and Food Chemistry, 2008, 56, 6923-6927.	5.2	30
106	Stereoselective Metabolism of Racemic Carvedilol by UGT1A1 and UGT2B7, and Effects of Mutation of these Enzymes on Glucuronidation Activity. Biological and Pharmaceutical Bulletin, 2007, 30, 2146-2153.	1.4	27
107	Evaluation of Effects of Polymorphism for Metabolic Enzymes on Pharmacokinetics of Carvedilol by Population Pharmacokinetic Analysis. Biological and Pharmaceutical Bulletin, 2007, 30, 537-542.	1.4	38
108	Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. European Journal of Pharmacology, 2007, 557, 1-8.	3.5	62

#	Article	IF	CITATIONS
109	Characterization of Secretory Intestinal Transport of Phenolsulfonphthalein. Drug Metabolism and Pharmacokinetics, 2005, 20, 72-78.	2.2	14
110	Phenolsulfonphthalein transport by potential-sensitive urate transport system. European Journal of Pharmacology, 2005, 518, 83-89.	3.5	3
111	The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. European Journal of Pharmaceutical Sciences, 2005, 26, 1-8.	4.0	57
112	Structure–affinity relationship in the interactions of human organic anion transporter 1 with caffeine, theophylline, theobromine and their metabolites. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1714, 85-92.	2.6	31
113	Absorption of Ester Prodrugs in Caco-2 and Rat Intestine Models. Antimicrobial Agents and Chemotherapy, 2004, 48, 2604-2609.	3.2	29
114	Expression of slc5a8 in Kidney and Its Role in Na+-coupled Transport of Lactate. Journal of Biological Chemistry, 2004, 279, 44522-44532.	3.4	140
115	Comparison of the Disposition Behavior of Organic anions in an Animal Model for Wilson's Disease (Long-Evans Cinnamon rats) with that in Normal Long-Evans Agouti rats. Drug Metabolism and Pharmacokinetics, 2004, 19, 150-154.	2.2	12
116	The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients. Clinical Transplantation, 2004, 18, 124-129.	1.6	9
117	A new system for the prediction of drug absorption using a pHâ€controlled Cacoâ€2 model: Evaluation of pHâ€dependent soluble drug absorption and pHâ€dependent soluble drug absorption absorpti absorpti	3.3	22
118	Comparison of urinary excretion of phenolsulfonphthalein in an animal model for Wilson's disease (Long-Evans Cinnamon rats) with that in normal Wistar rats: involvement of primary active organic anion transporter. Journal of Pharmacy and Pharmaceutical Sciences, 2004, 7, 227-34.	2.1	6
119	Major role of organic anion transporters in the uptake of phenolsulfonphthalein in the kidney. European Journal of Pharmacology, 2003, 475, 85-92.	3.5	16
120	An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs. International Journal of Pharmaceutics, 2003, 263, 35-44.	5.2	46
121	Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts. Clinical Transplantation, 2003, 17, 412-416.	1.6	9
122	Differential binding of disopyramide and warfarin enantiomers to human α1 -acid glycoprotein variants. British Journal of Clinical Pharmacology, 2003, 56, 664-669.	2.4	29
123	Uptake of dipeptide and $\hat{l}^2$ -lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1609, 39-44.	2.6	7
124	Mechanism of Active Secretion of Phenolsulfonphthalein in the Liver via Mrp2 (abcc2), an Organic Anion Transporter. Drug Metabolism and Pharmacokinetics, 2003, 18, 238-244.	2.2	23
125	Inhibitory Effects of Basic Drugs on the Sodium-Dependent Transport of L-Alanine via System B0 in the Small Intestine. Drug Metabolism and Pharmacokinetics, 2003, 18, 186-193.	2.2	1
126	lonic strength has a greater effect than does transmembrane electric potential difference on permeation of tryptamine and indoleacetic acid across Caco-2 cells. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 149-155.	2.6	6

#	Article	IF	CITATIONS
127	Age- and gender-related differences in carbohydrate concentrations of α 1 -acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. European Journal of Clinical Pharmacology, 2002, 58, 621-628.	1.9	25
128	Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 289-294.	2.3	40
129	Disribution of Irinotecan to Pleural and Pericardial Fluids in Patients with Lung Cancer Japanese Journal of Clinical Pharmacology and Therapeutics, 2002, 33, 47-52.	0.1	0
130	Absorption Profile in the Patients with Gatric Cancer after Gastrectomy Japanese Journal of Clinical Pharmacology and Therapeutics, 2002, 33, 67-72.	0.1	1
131	Structure, Function, and Tissue Expression Pattern of Human SN2, a Subtype of the Amino Acid Transport System N. Biochemical and Biophysical Research Communications, 2001, 281, 1343-1348.	2.1	112
132	Evidence for the transport of neutral as well as cationic amino acids by ATA3, a novel and liver-specific subtype of amino acid transport system A. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1510, 10-17.	2.6	105
133	Involvement of transporter recruitment as well as gene expression in the substrate-induced adaptive regulation of amino acid transport system A. Biochimica Et Biophysica Acta - Biomembranes, 2001, 1512, 15-21.	2.6	98
134	Cloning and functional characterization of a new subtype of the amino acid transport system N. American Journal of Physiology - Cell Physiology, 2001, 281, C1757-C1768.	4.6	104
135	Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. International Journal of Pharmaceutics, 2001, 221, 87-94.	5.2	85
136	Transport of Valganciclovir, a Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2. Journal of Pharmaceutical Sciences, 2000, 89, 781-789.	3.3	275
137	cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1492, 145-154.	2.4	84
138	Primary Structure, Genomic Organization, and Functional and Electrogenic Characteristics of Human System N 1, a Na+- and H+-coupled Glutamine Transporter. Journal of Biological Chemistry, 2000, 275, 23707-23717.	3.4	94
139	Cloning of an Amino Acid Transporter with Functional Characteristics and Tissue Expression Pattern Identical to That of System A. Journal of Biological Chemistry, 2000, 275, 16473-16477.	3.4	241
140	β-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter. Journal of Biological Chemistry, 2000, 275, 1699-1707.	3.4	156
141	Cloning and Functional Expression of ATA1, a Subtype of Amino Acid Transporter A, from Human Placenta. Biochemical and Biophysical Research Communications, 2000, 273, 1175-1179.	2.1	106
142	Primary structure, functional characteristics and tissue expression pattern of human ATA2, a subtype of amino acid transport system A. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1467, 1-6.	2.6	144
143	Structure and function of ATA3, a new subtype of amino acid transport system A, primarily expressed in the liver and skeletal muscle. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1509, 7-13.	2.6	125
144	Reactions of bis(silyl)palladium(II) complexes with allyl halides. Synthesis of mono(silyl)palladium(II) halides and X-ray structure of trans-PdCl(SiF2Ph)(PMe2Ph)2. Inorganica Chimica Acta, 1999, 296, 19-25.	2.4	12

MITSURU SUGAWARA

#	Article	IF	CITATIONS
145	Effects of interactions between drugs on the renal excretion of trientine in rats-acetazolamide and furosemide increase trientine excretion. Pharmaceutical Research, 1999, 16, 1888-1892.	3.5	2
146	A General Approach for the Prediction of the Intestinal Absorption of Drugs: Regression Analysis Using the Physicochemical Properties and Drug–Membrane Electrostatic Interaction. Journal of Pharmaceutical Sciences, 1998, 87, 960-966.	3.3	52
147	Purification and liposomal reconstitution of the oligopeptide transport activity in rat renal cortex using ceftibuten-affinity chromatography. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1368, 329-337.	2.6	2
148	Purification by ceftibuten-affinity chromatography and the functional reconstitution of oligopeptide transporter(s) in rat intestinal brush-border membrane. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1370, 161-168.	2.6	7
149	Mechanism of the inhibitory effect of imipramine on the Na+-dependent transport of l-glutamic acid in rat intestinal brush-border membrane. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1370, 252-258.	2.6	5
150	The Effect of Membrane Surface Potential on the Permeability of Anionic Compounds Across the Apical Membrane in Human Intestinal Epithelial (Caco-2) Cells Biological and Pharmaceutical Bulletin, 1997, 20, 794-799.	1.4	7
151	Single-step isolation method for six glycoforms of human α1-acid glycoprotein by hydroxylapatite chromatography and study of their binding capacities for disopyramide. Biomedical Applications, 1997, 703, 1-6.	1.7	14
152	EXCRETION MECHANISM OF POLYAMINE DRUGS FROM THE KIDNEY. Drug Metabolism and Pharmacokinetics, 1997, 12, 76-77.	0.0	0
153	Effect of cationic drugs on Na <sup>+</sup> -dependent carrier mediated transport and its evaluation. Drug Metabolism and Pharmacokinetics, 1997, 12, 74-75.	0.0	Ο
154	Transport mechanisms of nucleosides and the derivative, 6-mercaptopurine riboside across rat intestinal brush-border membranes. Biochimica Et Biophysica Acta - Biomembranes, 1996, 1278, 105-110.	2.6	12
155	Solubilization and reconstitution characteristics of the carrier protein(s) responsible for the transport of ceftibuten, a substrate for the oligopeptide transporters, in rat renal brush-border membrane. Biochimica Et Biophysica Acta - Biomembranes, 1996, 1283, 185-191.	2.6	8
156	Predicting the intestinal absorption of drugs by measuring their physicochemical properties. Drug Metabolism and Pharmacokinetics, 1996, 11, 5108-5109.	0.0	0
157	Changes in the Binding Capacity of Alpha-1-Acid Clycoprotein in Patients with Renal Insufficiency. Therapeutic Drug Monitoring, 1995, 17, 449-453.	2.0	13
158	Alphaâ€lâ€Acid Glycoprotein Concentration and the Protein Binding of Disopyramide in Healthy Subjects. Journal of Clinical Pharmacology, 1995, 35, 510-514.	2.0	22
159	Transport Mechanisms of Enoxacin in Rat Brush-Border Membrane of Renal Cortex: Interaction with Organic Cation Transport System and Ionic Diffusion Potential Dependent Uptake Biological and Pharmaceutical Bulletin, 1995, 18, 342-346.	1.4	5
160	Purification method for α-1-acid glycoprotein with subsequent high-performance liquid chromatographic determination of monosaccharides in plasma of healthy subjects and patients with renal insufficiency. Biomedical Applications, 1995, 672, 199-205.	1.7	13
161	The intestinal transport mechanism of fluoroquinolones: inhibitory effect of ciprofloxacin, an enoxacin derivative, on the membrane potential-dependent uptake of enoxacin. Pharmaceutical Research, 1995, 12, 1299-1303.	3.5	9
162	Transport mechanism of ceftibuten, a dianionic cephem, in rat renal brush-border membrane. Pharmaceutical Research, 1995, 12, 605-608.	3.5	10

#	Article	IF	CITATIONS
163	Comparison of the transport characteristics of ceftibuten in rat renal and intestinal brush-border membranes. Biochimica Et Biophysica Acta - Bioenergetics, 1995, 1231, 163-168.	1.0	16
164	Effect of membrane surface potential on the uptake and the inhibition of cationic compounds in rat intestinal brush-border membrane vesicles and liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1234, 22-28.	2.6	13
165	Changes in the permeation rate of organic anions through the intestinal brush-border membrane with membrane surface potential. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1190, 85-90.	2.6	9
166	Effect of membrane surface potential on the uptake of anionic compounds by liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1192, 241-246.	2.6	10
167	A New Reactive System for Catalytic Bis-Silylation of Acetylenes and Olefins. Organometallics, 1994, 13, 3237-3243.	2.3	100
168	STUDIES ON THE MECHANISMS FOR INTESTINAL ABSORPTION AND RENAL EXCRETION OF QUINOLONE ANTIBACTERIAL AGENTS. Drug Metabolism and Pharmacokinetics, 1994, 9, 110-113.	0.0	0
169	EFFECT OF MEMBRANE SURFACE POTENTIAL ON THE PERMEATION OF IONIC DRUGS THROUGH THE INTESTINAL BRUSH-BORDER MEMBRANE. Drug Metabolism and Pharmacokinetics, 1994, 9, 62-65.	0.0	0
170	The diversity of Na+-independent uptake systems for polyamines in rat intestinal brush-border membrane vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1151, 161-167.	2.6	22
171	The transport mechanisms of organic cations and their zwitterionic derivatives across rat intestinal brush-border membrane. II. Comparison of the membrane potential effect on the uptake by membrane vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1152, 9-14.	2.6	18
172	The transport mechanisms of organic cations and their zwitterionic derivatives across rat intestinal brush-border membrane. 1. Binding characteristics to the bio- and lipid-membranes. Biochimica Et Biophysica Acta - Biomembranes, 1993, 1146, 121-126.	2.6	10
173	MECHANISM OF POLYAMINES TRANSPORT BY RAT INTESTINAL EPITHELIAL CELL MEMBRANE. Drug Metabolism and Pharmacokinetics, 1993, 8, 743-746.	0.0	0
174	Carrier-mediated transport system for choline and its related quaternary ammonium compounds on rat intestinal brush-border membrane. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1112, 153-160.	2.6	38
175	Membrane-potential-dependent uptake of tryptamine by rat intestinal brush-border membrane vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1111, 145-150.	2.6	19
176	Rapid and simple method for the determination of α1-acid glycoprotein in serum by column liquid chromatography. Biomedical Applications, 1992, 582, 246-248.	1.7	7